Date receipt dossier
EudraCT number
2016-002543-41
Company / Sponsor
Janssen-Cilag International NV
Phase
Ib/II
Treated organism
Humans
Indication category
Cancer therapy
Disease
Advanced adenocarcinoma of the lung
Therapeutic approach
Immunotherapy
Genetic modification
Genetically modified, live attenuated Listeria monocytogenes (Lm ΔactA/ΔinlB)
Method of transfer of nucleic acid of interest
not applicable
Administered biological material
Genetically modified, attenuated Listeria monocytogenes (Lm ΔactA/ΔinlB) - JNJ-(64041)757
Route of administration
Intravenous
Locations in Belgium
AZ Maria Middelares, Gent
Nr of subjects
9
Type of procedure
Contained use only
Current status
Authorized